Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CytoMed Therapeutics Limited ( (GDTC) ) has provided an announcement.
CytoMed Therapeutics Limited has called its Annual General Meeting of shareholders for May 22, 2026, in Singapore, with an option for overseas investors to follow proceedings via a live webcast. The agenda includes adopting the 2025 financial statements, re-electing two directors, approving a waiver from the Singapore Code on Take-overs and Mergers, appointing auditors, setting directors’ fees, and granting broad authority to the board to issue new shares and instruments under Singapore law and Nasdaq rules, a move that could facilitate future capital raising and potentially dilute existing shareholders.
Shareholders must be on record as of May 19, 2026, for their proxy votes to count, despite voting materials being sent based on an April 10, 2026, mailing record date. The proposed authority to issue additional shares and securities signals CytoMed’s preparation for future fundraising or follow-on offerings, reinforcing its financial flexibility while highlighting governance and dilution considerations for investors.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
The score is primarily constrained by weak financial performance driven by persistent losses and continued cash burn, despite some balance-sheet improvement. Technicals add additional caution as the stock trades below major moving averages with soft momentum. Valuation is difficult to support using P/E due to negative earnings, and no dividend yield data is available.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based biotechnology company listed on Nasdaq and focused on developing cell-based immunotherapies. Operating from its headquarters at One Commonwealth in Singapore, the company targets global capital markets to fund its research and development and broader commercialization plans.
Average Trading Volume: 532,705
Technical Sentiment Signal: Sell
Current Market Cap: $11.83M
For a thorough assessment of GDTC stock, go to TipRanks’ Stock Analysis page.